Some endocrine hormones level associated with Chronic myelogenous leukemia patients in Al Anbar governorate
DOI:
https://doi.org/10.52783/jns.v14.1775Keywords:
Leukemia, endocrine hormones, Immune Response, Erythropoietin (EPO), Parathyroid hormone (PTH), Homocystine(THcy)Abstract
Background and Objective: Leukemias are linked to numerous immunological and endocrine alterations. Numerous studies have demonstrated an association between endocrine hormone imbalance and the onset of disease in one or both sexes. Hormonal fluctuations can disrupt the physiological homogeneity of the human body, hence impacting health and the progression of associated disorders. We want to examine the impact of changes in endocrine hormones on the immunological response of persons with leukemia.
Materials and Methods: This case-control study enrolled 110 individuals, including 90 patients diagnosed with hematological malignancy, at the Medical City Department/Hematology Center in Baghdad, Iraq, from March to November 2024. Among 90 individuals diagnosed with leukemia, 70 were identified with sever chronic myeloid leukemia (CML1), whereas 20 were classed with moderate chronic myeloid leukemia (CML2) based on the disease duration. The research included 20 healthy participants as controls. Erythropoietin (EPO), homocysteine (THcy), parathyroid hormone (PTH), vitamin B12, vitamin D3, and folate levels were assessed in all individuals using both ELISA and immunofluorescence test methods. Calcitonin (Cal) and ferritin were also measured.
Results: The study's findings revealed a substantial increase in calcitonin (Cal) and ferritin levels (P < 0.001) in the experimental group compared to the control group. Serum Parathyroid hormone (PTH) levels were elevated in patients diagnosed with the CML1 and CML2 groups compared to the control group (P = 0.01). Erythropoietin (EPO) levels were significantly higher (P = 0.02) in both the CML1 and CML2 groups. The difference was shown to be statistically significant. Both CML1 and CML2 patients had significantly reduced levels of B12 and VD3 in comparison to the control group (P = 0.01 and 0.02, respectively). For Homocystine and Folate (p = 0.004, 0.001, respectively). he study's findings provide concrete evidence for the influence of hormones on the immune response in the etiology of leukemia.
Downloads
Metrics
References
Al-Guburi, N. A. S. (2016). The Role of Plasma Homocysteine Level in Leukemia Disease and its Relationship with the Blood Component The White Blood Cell and Hemoglobin in Patients Tikrit-Iraq.
Savla SR, Prabhavalkar KS, Bhatt LK. Liver X receptor: A potential target in the treatment of atherosclerosis. Expert Opin Ther Targets. 2022;26(7):645–58.
Sciacchitano S, De Vitis C, D’Ascanio M, Giovagnoli S, De Dominicis C, Laghi A, et al. Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies. J Transl Med. 2021 Apr 1;19(1):139.
Su H, Zhou X, Zhao Y, Lu Y, Liu D, Zhang J, et al. Gynecological complications in long-term survivors after allogeneic hematopoietic cell transplantation-a single-center real-life cross-sectional study. Front Med (Lausanne). 2022;9:956867.
Yang X, Yin H, Xiao C, Li R, Liu Y. The Prognostic Significance of C-Reactive Protein to Albumin Ratio in Patients With Severe Fever With Thrombocytopenia Syndrome. Front Med (Lausanne). 2022;9:879982
Amin MN, Permatasari N. The Role of Stem Cell on Orthodontic Tooth Movement Induced-Alveolar Bone Remodeling. Res J Pharm Technol. 2023;16(1):123–8.
Sendes waleed S. k.(2012). Effects of chronic myeloid leukemia on some haematological parameters and indicators during chemotherapy period. Tikr Med J, 8, 229-235
Larrue, C., Guiraud, N., Mouchel, P. L., Dubois, M., Farge, T., Gotanègre, M., ... & Sarry, J. E. (2021). Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. Nature communications, 12(1), 422.
Angenendt, L., Bormann, E., Pabst, C., Alla, V., Görlich, D., Braun, L., ... & Schliemann, C. (2019). The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. Leukemia, 33(12), 2830-2841.
Pham, T. N. D., Ma, W., Miller, D., Kazakova, L., & Benchimol, S. (2019). Erythropoietin inhibits chemotherapy-induced cell death and promotes a senescence-like state in leukemia cells. Cell death & disease, 10(1), 22.
Hussein, A. H. A., Mohammad, N. B. A. A., & Farhood, R. G. (2023). Serum erythropoietin level in anemic and non-anemic patients with chronic leukemia. Medical Journal of Babylon, 20(4), 739-744.
Cesini, L., Frieri, C., Baratè, C., Sorà, F., Cerrano, M., Cagnetta, A., ... & Latagliata, R. (2017). Role of Erythropoietin in the Late Anemia of Patients with Chronic Myeloid Leukemia Treated Frontline with Imatinib. Blood, 130, 2884.
Jumaah, H. M., Yenzeel, J. H., & Mehdi, M. G. (2021). Evaluation of some biochemical parameters and hormones in patients with acute myeloid leukemia in Iraq. Iraqi Journal of Science, 1460-1466.
Atoum, M. F., Alzoughool, F. E., Al-Mazaydeh, Z. A., Rammaha, M. S., & Tahtamouni, L. H. (2022). Vitamin B12 enhances the antitumor activity of 1, 25-dihydroxyvitamin d 3 via activation of caspases and targeting actin cytoskeleton. Tumor Biology, 44(1), 17-35.
Ahmood, A. A., Mohammed, M. J., & Taha, M. M. (2024). Alterations in Physiological Parameters Osteocalcin, Osteonectin, Osteopontin, Vitamin D, Vaspin and Visfatin in Rheumatoid Arthritis and Osteoarthritis Patients. Afr.J.Bio.SC,6,5941-5981.
Shafie, M., Issaiy, M., Barkhori, M., & Parsa, S. (2022). Plasma cell leukemia presenting as spontaneous tumor lysis syndrome with hypercalcemia. Clinical Case Reports, 10(7), e05933.
Halczuk, K., Kaźmierczak-Barańska, J., Karwowski, B. T., Karmańska, A., & Cieślak, M. (2023). Vitamin B12—Multifaceted in vivo functions and in vitro applications. Nutrients, 15(12), 2734.
Al-Anzy, M. M. Y., & Salih, N. A. (2007). Serum Alkaline Phosphatase, Iron and Calcium Levels in BreastCancer and Leukemia Patients in Salah Al-Din Province. Tikrit Journal of Pharmaceutical Sciences, 3(2), 147-151.
Łęcka, M., Czyżewski, K., Dębski, R., Wysocki, M., & Styczyński, J. (2021). Impact of ferritin serum concentration on survival in children with acute leukemia: a long-term follow-up. Acta Haematologica Polonica, 52(1), 54-60.
Zekavat, O. R., Tafti, F. F., Bordbar, M., Parand, S., & Haghpanah, S. (2024). Iron overload in children with leukemia; identification of a cutoff value for serum ferritin level. Journal of Pediatric Hematology/Oncology, 46(2), e137-e142.
Kohart, N. A., Elshafae, S. M., Demirer, A. A., Dirksen, W. P., Breitbach, J. T., Shu, S. T., ... & Rosol, T. J. (2020). Parathyroid hormone-related protein promotes bone loss in T-cell leukemia as well as in solid tumors. Leukemia & lymphoma, 61(2), 409-419.
Metayer, C., Imani, P., Dudoit, S., Morimoto, L., Ma, X., Wiemels, J. L., & Petrick, L. M. (2023). One-carbon (folate) metabolism pathway at birth and risk of childhood acute lymphoblastic leukemia: a biomarker study in newborns. Cancers, 15(4), 1011.
Lightfoot, T. J., Johnston, W. T., Painter, D., Simpson, J., Roman, E., Skibola, C. F., ... & Taylor, G. M. (2010). Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood, The Journal of the American Society of Hematology, 115(19), 3923-3929.
Chen, X., Jin, J., Chang, R., Yang, X., Li, N., Zhu, X., ... & Li, Y. (2024). Targeting the sulfur-containing amino acid pathway in leukemia. Amino Acids, 56(1), 47.
Cunningham, A., Erdem, A., Alshamleh, I., Geugien, M., Pruis, M., Pereira-Martins, D. A., ... & Schuringa, J. J. (2022). Dietary methionine starvation impairs acute myeloid leukemia progression. Blood, The Journal of the American Society of Hematology, 140(19), 2037-2052.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
